Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

31.70 +0.47 (+1.50%)
Streaming Delayed Price Updated: 3:07 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
Preview: Vaxcyte's Earnings
 
Via Benzinga
Expert Ratings for Vaxcyte
 
Via Benzinga
Why Shares of Vaxcyte Rose 110.7% This Week
The company released early data for a promising pneumonia vaccine. 
Via The Motley Fool
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
From Vaxcyte, Inc.
Via GlobeNewswire
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst
 
Via Benzinga
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
 
Via Benzinga
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Vaxcyte to Present at Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
Why Investors Are Suddenly Excited About Vaxcyte
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet. 
Via MarketBeat
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Vaxcyte Announces Pricing of $600 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
Avis Budget, Scholastic And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Dow Rises 1.5%; Nasdaq Jumps Over 100 Points
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. 
Via Benzinga
Why Vaxcyte Shares Are Trading Sharply Higher? Here Are 63 Stocks Moving In Monday's Mid-Day Session
Gainers Vaxcyte, Inc. (NASDAQ: PCVX) shares jumped 65% to $33.96 after the company announced positive topline results from the Phase 1/2 clinical proof-of-concept study evaluating the safety,... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.